首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Impaired continence function five years after intensified chemoradiation in patients with locally advanced rectal cancer
【24h】

Impaired continence function five years after intensified chemoradiation in patients with locally advanced rectal cancer

机译:局部晚期直肠癌患者放化疗后5年的节制功能受损

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aims While the influence on survival is only seen in patients with complete regression after neoadjuvant treatment in locally advanced rectal cancer the impairment of the continence capacity weighs even more for patients with little oncological benefit. Methods Patients treated with intensified preoperative radiochemotherapy patients treated only by TME surgery were asked five years after treatment to complete the Wexner and SF-12 quality of life questionnaire. Results 25 after neoadjuvant treatment had a median Wexner score of 14 [3-20] after 63 [42-78] months. Histopathological stage or grade of regression did not influence the Wexner score (p = 0.76, resp. p = 0.9). 12% describe themselves as being permanently continent; 40% are stool incontinent "always" or "most of the time". 68% are always wearing pads. 29 patients after TME only showed a median Wexner score of 5 [range 0-17] after 66 months [26-133]. SF-12 showed significantly lower values in physical (p = 0.02) as well as mental summary scales (p = 0.015) in patients after RCTX while patients after radical surgery showed no difference to the norm population. Conclusion This study shows that continence is significantly worse five years after neoadjuvant treatment. Moreover, patients after neoadjuvant treatment and surgery have impaired quality of life compared to norm population. These results may contribute to the discussion of only applying neoadjuvant chemoradiation selectively in patients with advanced rectal cancer.
机译:目的虽然对生存的影响仅在局部晚期直肠癌新辅助治疗后完全消退的患者中可见,但对于几乎没有肿瘤学益处的患者,节制能力的损害甚至更大。方法对仅接受TME手术治疗的术前强化放化疗患者进行治疗,并在治疗后五年内填写Wexner和SF-12生活质量问卷。结果新辅助治疗后25,63 [42-78]个月后,韦克斯纳评分中位数为14 [3-20]。组织病理学阶段或消退程度不影响韦克斯纳评分(p = 0.76,p = 0.9)。 12%的人称自己是永久大陆; 40%是“总是”或“大部分时间”的大便失禁。 68%的人总是穿着护垫。在66个月后[26-133],TME后的29例患者仅显示中位Wexner评分为5 [范围0-17]。在RCTX之后,SF-12患者的身体状况(p = 0.02)和心理摘要量表(p = 0.015)显着较低,而根治性手术后的患者与正常人群无差异。结论这项研究表明,新辅助治疗后5年,尿失禁明显恶化。此外,与正常人群相比,新辅助治疗和手术后患者的生活质量受损。这些结果可能有助于讨论仅在晚期直肠癌患者中选择性应用新辅助化学放疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号